|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have demonstrated that aberrantly glycosylated cell surface proteins on tumor cells are amenable CAR targets.
|
30510550 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We present a functional analysis of TRIM13 using a loss-of-function approach, and demonstrate that TRIM13 downregulation decreases tumour cell survival as well as cell cycle progression and proliferation of MM cells.
|
23647456 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, male transgenic mice expressing human CAR and PXR were used to detect possible differences between wild-type (WT) and humanized mice in their response to CAR activation in a tumor initiation/promotion experiment with a single injection of the tumor initiator N-nitrosodiethylamine preceding chronic PB treatment for 10 months.
|
24863967 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In in vivo experiment, we confirmed how DOC enhanced the recruitment of HER2-CAR T cells to tumor sites.
|
30744691 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we engineered T cells with a CAR consisting of the extracellular domain of heregulin-1β (HRG1β) that is a natural ligand for HER3/HER4, and evaluated the specific cytotoxicity of these CAR-T cells in cultured HER3 positive breast cancer cells and xenograft tumors.
|
29127433 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While immunotherapy with chimeric antigen receptor T (CAR-T) cells has shown much promise in haematological malignancies, their efficacy for solid tumours is challenged by the lack of tumour-specific antigens required to avoid on-target, off-tumour effects.
|
30121627 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, lack of response to CAR T cell treatment is due in some cases to intrinsic autologous T cell defects and/or the inability of these cells to function optimally in a strongly immunosuppressive tumor microenvironment.
|
30735463 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ad-mTNFa-mIL2 increased both CAR T cell and host T cell infiltration to the tumor and altered host tumor immune status with M1 polarization of macrophages and increased dendritic cell maturation.
|
29618658 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, CD19-GITR-CD3 CAR-T cells had significant cytotoxic activity against CD19-positive cancer cells <i>in vitro</i> and in Raji xenograft tumors <i>in vivo</i>.
|
29772559 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe side effects.
|
30659408 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR is involved in the formation of epithelial tight junctions and promotes tumor growth in some cancers.
|
31512325 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we investigate a unique variant of familial hypercalcemia, unrelated to multiple endocrine neoplasia and hyperparathyroidism-jaw tumor syndromes, with hypercalcemia due to a point mutation in the intracellular part of the calcium receptor (CaR) gene.
|
12161540 |
2002 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BiTEs were secreted from the transferred T cells and enabled both the transferred and bystander T cells to specifically recognize CD19(+) cell lines, with increased tumor killing ability, prolonged functional persistence, increased cytokine production and potent proliferation compared with the CAR-T cells.
|
27258611 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with GSK3-inhibited CAR-T cells resulted in 100% tumor elimination during the tumor-rechallenge experiment in GBM-bearing animals and increased accumulation of memory CAR-T cells in secondary lymphoid organs.
|
29959057 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection.
|
30649750 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Human T cells expressing CAR targeting mesothelin or fibroblast activation protein and containing CD3ζ and 4-1BB cytoplasmic domains were intravenously injected into immunodeficient mice bearing large, established human mesothelin-expressing flank tumors.
|
24919573 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The obstacles that reduce the efficacy of CAR-T therapy in solid tumors include a lack of specific tumor antigens, limited trafficking and penetration of CAR-T cells to tumor sites, and an immunosuppressive tumor microenvironment.
|
29861325 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These responses are strictly limited and are tightly linked, since β-catenin is activated in nearly all of the CAR-dependent tumours generated by the tumour promoter phenobarbital.
|
25661872 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicated that the disruption of PD-1 enhanced the <i>in vivo</i> anti-tumor activity of CAR T cells against HCC, improved the persistence and infiltration of CAR T cells in the NSG mice bearing the tumor, and strengthened the inhibition of tumor-related genes expression in the xenograft tumors caused by the GPC3-CAR T cells.
|
30327605 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future.
|
30721445 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells lacking all three NR4A transcription factors (Nr4a triple knockout) promoted tumour regression and prolonged the survival of tumour-bearing mice.
|
30814732 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells bearing a functional chemokine receptor can overcome the inadequate tumor localization that limits conventional CAR targeting strategies and can significantly improve antitumor efficacy in vivo.
|
21610146 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell transfer therapy (ACT) using tumor infiltrating lymphocytes or lymphocytes redirected with antigen receptors (CAR or TCR) has revolutionized the field of cancer immunotherapy.
|
30842774 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establishment of guidelines for the production and application of CAR-T cells.
|
26965523 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Given that multiple genetic alterations are the main factors that drive genesis and development of tumor, CRISPR-Cas9 system has been applied to correct cancer-causing gene mutations and deletions and to engineer immune cells, such as chimeric antigen receptor T (CAR T) cells, for cancer immunotherapeutic applications.
|
29579146 |
2019 |